Lv1
90 积分 2023-10-07 加入
The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience
1个月前
已完结
The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience
1个月前
已关闭
A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity
1个月前
已完结
NaCl enhances CD8+ T cell effector functions in cancer immunotherapy
1个月前
已完结
Circulating exosomal CPNE3 as a diagnostic and prognostic biomarker for colorectal cancer
2个月前
已完结
Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial
4个月前
已完结
Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters-Reply
4个月前
已完结
Circulating exosomal CPNE3 as a diagnostic and prognostic biomarker for colorectal cancer
5个月前
已完结
Circulating exosomal CPNE3 as a diagnostic and prognostic biomarker for colorectal cancer
9个月前
已完结
Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies reveals potential therapeutic strategies
10个月前
已完结
皖公网安备34019202002308
